Table II.
Therapy | n (%) |
---|---|
VAD–Hyper CVAD | 113 (66) |
Cytarabine combinations | 20 (12) |
Allogeneic stem cell transplant | 14 (8) |
Methotrexate-asparaginase | 5 (3) |
Other combinations | 9 (5) |
Single agent | 11 (6) |
VAD, vincristine, doxorubicin, and dexamethasone; Hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.